Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

20.68 -0.74 (-3.45%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

23 24 Next >

Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 16, 2024

Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.

Via Benzinga

Why Sarepta Therapeutics Stock Is Soaring Today ↗

February 16, 2024

The biotech just scored a big FDA win with an even bigger one potentially coming by June.

Via The Motley Fool

Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday ↗

February 16, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.

Via Benzinga

Topics Stocks

In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics ↗

February 15, 2024

Via Benzinga

Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts ↗

January 30, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 16, 2024

Via Benzinga

2 Magnificent Growth Stocks to Buy With $500 ↗

February 15, 2024

No need to break the bank to invest in promising stocks.

Via The Motley Fool

Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗

February 12, 2024

Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.

Via Benzinga

1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? ↗

February 11, 2024

Bad news for one player does not always equal good news for another.

Via The Motley Fool

Decoding Bearish Analog And The Warning Signs You Can't Ignore ↗

February 07, 2024

A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore.

Via Talk Markets

Topics Stocks

A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics ↗

January 10, 2024

Via Benzinga

The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition ↗

February 06, 2024

Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.

Via InvestorPlace

Topics Artificial Intelligence

Sarepta Therapeutics' Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing ↗

January 29, 2024

Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.

Via Benzinga

Got $3,000? 3 Growth Stocks to Double Up On Right Now ↗

January 26, 2024

There's more to stock picking than comparing risk and reward. Finding the right position size for a particular stock is also important.

Via The Motley Fool

Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? ↗

January 25, 2024

It's always tough to be compared to a giant.

Via The Motley Fool

Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today ↗

January 22, 2024

One pundit feels there is solid potential in one of the company's more recently approved drugs.

Via The Motley Fool

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market ↗

January 16, 2024

In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.

Via InvestorPlace

Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday? ↗

January 09, 2024

Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the...

Via Benzinga

Topics Economy

Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year ↗

January 09, 2024

Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product

Via Benzinga

Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match ↗

January 09, 2024

Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.

Via InvestorPlace

Why Is Sarepta Therapeutics (SRPT) Stock Up Today? ↗

January 09, 2024

Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram.

Via InvestorPlace

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday ↗

January 09, 2024

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.

Via Benzinga

Topics Stocks

2 Growth Stocks That Could Make You Richer in 2024 and Beyond ↗

January 09, 2024

Last year wasn't great for either stock, but that's no reason to ignore them.

Via The Motley Fool

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 ↗

January 07, 2024

Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...

Via Talk Markets

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

3 Things About Sarepta Therapeutics Every Smart Investor Knows ↗

December 28, 2023

Mastering this stock requires appreciating a few scientific nuances.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

December 27, 2023

Via Benzinga

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗

December 22, 2023

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Via The Motley Fool

1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond ↗

December 17, 2023

Many investors are bailing out, but that might be a mistake.

Via The Motley Fool

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today